Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 4C6H11NO.Cl.Cu |
| Molecular Weight | 551.63 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cu+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]
InChI
InChIKey=HTNSWSXDHPANFY-UHFFFAOYSA-M
InChI=1S/4C6H11NO.ClH.Cu/c4*1-6(2,8-4)5-7-3;;/h4*5H2,1-2,4H3;1H;/q;;;;;+1/p-1
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | TECHNETIUM TC 99M SESTAMIBI Approved UseTechnetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Launch Date1990 |
|||
| Diagnostic | TECHNETIUM TC 99M SESTAMIBI Approved UseTechnetium Tc 99m Sestamibi is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Launch Date1990 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XA9ZKK5FZ2
Created by
admin on Mon Mar 31 17:46:25 GMT 2025 , Edited by admin on Mon Mar 31 17:46:25 GMT 2025
|
PRIMARY | |||
|
161566-74-1
Created by
admin on Mon Mar 31 17:46:25 GMT 2025 , Edited by admin on Mon Mar 31 17:46:25 GMT 2025
|
PRIMARY | |||
|
133082316
Created by
admin on Mon Mar 31 17:46:25 GMT 2025 , Edited by admin on Mon Mar 31 17:46:25 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
